E
Equillium, Inc. (EQ)
NCM – Real vaqt narxi. Valyuta: USD
2.27
+0.02 (0.89%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
2.27
+0.02 (0.89%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Equillium, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Qo'shma Shtatlarda og'ir autoimmün va yallig'lanish yoki immuno-yallig'lanish kasalliklarini davolash uchun terapevtik vositalarni ishlab chiqadi. Kompaniya yarali kolit va o'pka yallig'lanishi kasalliklarini davolash uchun preklinik bosqichda bo'lgan yangi AhR modulyatori EQ504ni ishlab chiqadi. Shuningdek, u setsiyaning kasalliklarini davolash uchun og'iz orqali yuborish uchun ishlab chiqilgan IL-15 va IL-21 ning ikki tomonlama ingibitori EQ302ni ishlab chiqadi. Kompaniya ilgari Attenuate Biopharmaceuticals, Inc. nomi bilan tanilgan va 2017 yil may oyida Equillium, Inc. nomini o'zgartirgan. Equillium, Inc. 2017 yilda ro'yxatga olingan va shtab-kvartirasi La Jolla, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Lisette Acevedo | Vice President of Clinical Development |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer & President |
| Mr. Bruce D. Steel C.F.A. | Co-Founder, CEO & Director |
| Mr. Michael Moore | Vice President of Investor Relations & Corporate Communications |
| Ms. Christine Zedelmayer M.B.A., P.M.P. | Senior VP & COO |
| Ms. Penny Tom CPA | Senior VP of Finance & Principal Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-15 | DEFA14A | eq-defa14a-2026.htm |
| 2026-04-15 | DEF 14A | eq-20260414.htm |
| 2026-04-07 | S-3 | d116924ds3.htm |
| 2026-03-30 | PRE 14A | eq-20260330.htm |
| 2026-03-25 | S-8 | d25194ds8.htm |
| 2026-03-13 | 8-K | d125584d8k.htm |
| 2025-11-13 | S-3 | d53133ds3.htm |
| 2025-11-13 | 8-K | eq-20251113.htm |
| 2025-10-24 | 8-K/A | eq-20250930.htm |
| 2025-10-06 | 8-K | d930780d8k.htm |